EPS for AIT Therapeutics, Inc. (AITB) Expected At $-0.35

May 16, 2018 - By Hannah Black

Analysts expect AIT Therapeutics, Inc. (OTCMKTS:AITB) to report $-0.35 EPS on May, 21.After having $-0.28 EPS previously, AIT Therapeutics, Inc.’s analysts see 25.00 % EPS growth. The stock decreased 0.34% or $0.01 during the last trading session, reaching $2.92. About shares traded. AIT Therapeutics, Inc. (OTCMKTS:AITB) has 0.00% since May 16, 2017 and is . It has underperformed by 11.55% the S&P500.

AIT Therapeutics, Inc., a biopharmaceutical company, engages in developing a single proprietary formulation of 160 parts per million of nitric oxide and delivery systems to treat respiratory infections. The company has market cap of $24.52 million. The company's pipeline includes therapies against respiratory infections in acute and chronic diseases, such as severe bronchiolitis , cystic fibrosis related lung infections (CF), and non-tuberculosis mycobacterial (NTM) infections. It currently has negative earnings. It has completed two Phase II trials to treat RSV and CF related lung infections, as well as conducted a treatment for patients with CF who suffer from NTM infections.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: